Printer Friendly

FDA Accepts Resubmission of New Drug Application for Duobrii Lotion.

M2 PHARMA-August 30, 2018-FDA Accepts Resubmission of New Drug Application for Duobrii Lotion

(C)2018 M2 COMMUNICATIONS

- The US Food and Drug Administration has accepted the resubmitted New Drug Application for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis, prescription dermatology health care businesses Ortho Dermatologics said.

The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of February 15, 2019.

If approved, Duobrii will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

About Ortho Dermatologics

Ortho Dermatologics, a Bausch Health company, is one of the largest prescription dermatology businesses in the world dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses.

The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and anti-infective products.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 30, 2018
Words:179
Previous Article:KinoPharma , National Institutes for Quantum and Radiological Science and Technology Launch Collaborative Research Project for Exploring New Drug...
Next Article:GSK granted licence extension for Nucala in Europe.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters